<div id="readability-page-1"><p>Norden Group LLC lifted its holdings in  Boston Scientific Corporation (NYSE:BSX - Free Report) by 442.2% in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The fund owned 15,257 shares of the medical equipment provider's stock after acquiring an additional 12,443 shares during the period. Norden Group LLC's holdings in Boston Scientific were worth $1,490,000 at the end of the most recent quarter.</p><div><p><span></span><span>Get <strong>Boston Scientific</strong> alerts:</span></p></div><ul><li>Beware the Death Cross: 3 Stocks Triggering This Spooky Signal</li></ul><p>Other large investors also recently added to or reduced their stakes in the company. World Investment Advisors boosted its holdings in shares of  Boston Scientific by 12.4% in the 3rd quarter. World Investment Advisors now owns 18,954 shares of the medical equipment provider's stock worth $1,850,000 after purchasing an additional 2,084 shares during the period.  Tritonpoint Wealth LLC lifted its position in  Boston Scientific by 4.0% in the third quarter. Tritonpoint Wealth LLC now owns 3,503 shares of the medical equipment provider's stock worth $342,000 after buying an additional 136 shares during the last quarter.  Brookstone Capital Management boosted its stake in  Boston Scientific by 12.0% during the third quarter. Brookstone Capital Management now owns 129,321 shares of the medical equipment provider's stock worth $12,626,000 after buying an additional 13,906 shares during the period.  Private Trust Co. NA boosted its stake in  Boston Scientific by 7.2% during the third quarter. Private Trust Co. NA now owns 3,986 shares of the medical equipment provider's stock worth $389,000 after buying an additional 268 shares during the period.  Finally, Southland Equity Partners LLC increased its position in  Boston Scientific by 9.8% during the third quarter. Southland Equity Partners LLC now owns 2,344 shares of the medical equipment provider's stock valued at $229,000 after acquiring an additional 210 shares during the last quarter. 89.07% of the stock is owned by institutional investors. </p><h2>Insider Activity</h2><p>In other Boston Scientific news, Director Ellen M. Zane sold 12,891 shares of the company's stock in a transaction on Thursday, November 6th. The stock was sold at an average price of $98.28, for a total transaction of $1,266,927.48. Following the completion of the sale, the director owned 24,134 shares in the company, valued at $2,371,889.52. This represents a 34.82% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at the SEC website. Also, EVP Arthur C. Butcher sold 17,313 shares of Boston Scientific stock in a transaction on Monday, December 1st. The shares were sold at an average price of $101.55, for a total value of $1,758,135.15. Following the completion of the transaction, the executive vice president owned 23,600 shares in the company, valued at $2,396,580. This represents a 42.32% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 143,095 shares of company stock worth $14,228,950. 0.50% of the stock is currently owned by corporate insiders. </p><h2>Boston Scientific Trading Down 0.1%</h2><ul><li>3 Healthcare Stocks Using AI to Drive Growth</li></ul><p>Shares of NYSE BSX opened at $96.00 on Friday. Boston Scientific Corporation has a twelve month low of $85.98 and a twelve month high of $109.50. The firm has a market cap of $142.31 billion, a PE ratio of 51.34, a price-to-earnings-growth ratio of 1.94 and a beta of 0.67. The business has a fifty day simple moving average of $98.60 and a two-hundred day simple moving average of $101.10. The company has a quick ratio of 0.96, a current ratio of 1.51 and a debt-to-equity ratio of 0.47. </p><p>Boston Scientific (NYSE:BSX - Get Free Report) last posted its quarterly earnings results on Wednesday, October 22nd. The medical equipment provider reported $0.75 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.71 by $0.04. The business had revenue of $5.07 billion for the quarter, compared to the consensus estimate of $4.97 billion. Boston Scientific had a return on equity of 19.46% and a net margin of 14.43%.The business's revenue was up 20.3% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.63 EPS. Boston Scientific has set its FY 2025 guidance at 3.020-3.040 EPS and its Q4 2025 guidance at 0.770-0.790 EPS.  Analysts expect that  Boston Scientific Corporation will post 2.85 earnings per share for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><ul><li>3 Biotech Catalysts Present Major Opportunity</li></ul><p>BSX has been the subject of several analyst reports. Weiss Ratings  restated a &#34;buy (b-)&#34; rating on shares of Boston Scientific in a report on Wednesday, October 8th. Royal Bank Of Canada increased their price target on Boston Scientific from $125.00 to $130.00 and gave the stock an &#34;outperform&#34; rating in a report on Wednesday, December 17th. BTIG Research  reissued a &#34;buy&#34; rating and set a $132.00 price target on shares of Boston Scientific in a research note on Friday, November 21st. Wells Fargo &amp; Company upped their price objective on Boston Scientific from $124.00 to $125.00 and gave the company an &#34;overweight&#34; rating in a research report on Thursday, October 23rd. Finally, UBS Group  reiterated a &#34;buy&#34; rating on shares of Boston Scientific in a research report on Wednesday, December 17th. Two investment analysts have rated the stock with a Strong Buy rating, twenty have issued  a Buy rating and two have issued  a Hold rating to the stock. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Buy&#34; and a consensus price target of $124.85.</p><p><b>View Our Latest Report on Boston Scientific</b></p><h2>Boston Scientific Company Profile</h2> (Free Report)<p>Boston Scientific Corporation <span>NYSE: BSX<span></span></span> is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.  </p><p>Boston Scientific's activities span product development, clinical research, regulatory affairs and commercial sales.</p><h2>Featured Articles</h2><ul><li>Five stocks we like better than Boston Scientific</li><li>Turn your &#34;dead money&#34; into $306+ monthly (starting this month)</li><li>Buffett, Gates and Bezos Quietly Dumping Stocks—Here's Why</li><li>Washington prepares for war</li><li>Put $1,000 into this stock by Jan 1 [Not NVDA]</li><li>The McDonald's Secret</li></ul><p><strong>Want to see what other hedge funds are holding BSX?</strong> Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Boston Scientific Corporation (NYSE:BSX - Free Report).</p><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="350" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUJTWA"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Boston Scientific Right Now?</h2><p>Before you consider Boston Scientific, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Boston Scientific wasn't on the list.</p><p>While Boston Scientific currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

<p>Norden Group LLC increased its holdings in Boston Scientific Corporation by 442.2% in Q3, now owning 15,257 shares valued at $1.49 million. Other investors also adjusted their stakes. Insider trading saw significant stock sales by Director Ellen M. Zane and EVP Arthur C. Butcher. Boston Scientific's Q3 earnings exceeded expectations with $0.75 EPS and $5.07 billion revenue. The company forecasts FY 2025 EPS of 3.020-3.040.</p>

Norden Group LLC Increases Holdings in Boston Scientific Corporation $BSX